Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor - Induced musculoskeletal pain: SWOG S0927

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1910-1917

  Hershman, Dawn L ^a   Unger, Joseph M ^b,c   Crew, Katherine D ^a   Awad, Danielle ^a   Dakhil, Shaker R ^d   Gralow, Julie ^c   Greenlee, Heather ^a   Lew, Danika L ^b,c   Minasian, Lori M ^e   Till, Cathee ^b,c   Wade, James L ^f   Meyskens, Frank L ^g   Moinpour, Carol M ^c  

^a Department of Medicine   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c USA   (United States)

^d Cancer Center of Kansas   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Central Illinois Community Clinical Oncology Program   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; C REACTIVE PROTEIN; EXEMESTANE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO; TAXANE DERIVATIVE; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT;

ARTHRALGIA; ARTICLE; BREAST CANCER; BRIEF PAIN INVENTORY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG USE; DYSPEPSIA; FEMALE; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MUSCULOSKELETAL SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SATISFACTION; POSTMENOPAUSE; QUESTIONNAIRE; SELF REPORT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL SYSTEM; NEOPLASM STAGING; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; SELF REPORT; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84937117762     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.5595     Document Type: Article

References (44)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
2. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
3. nd San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-13, 2009
4. Henry NL, Jacobson JA, Banerjee M, et al: A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116:4360-4367, 2010
5. Mao JJ, Stricker C, Bruner D, et al: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631-3639, 2009
6. Sestak I, Cuzick J, Sapunar F, et al: Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis. Lancet Oncol 9:866-872, 2008
7. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010
8. Leslie CA, Gonnerman WA, Ullman MD, et al: Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. J Exp Med 162:1336-1349, 1985
9. Cleland LG, French JK, Betts WH, et al: Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol 15:1471-1475, 1988
10. Sundrarjun T, Komindr S, Archararit N, et al: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. J Int Med Res 32:443-454, 2004
11. Kremer JM, Bigauoette J, Michalek AV, et al: Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1:184-187, 1985
12. Kremer JM, Lawrence DA, Jubiz W, et al: Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: Clinical and immunologic effects. Arthritis Rheum 33:810-820, 1990
13. Nielsen GL, Faarvang KL, Thomsen BS, et al: The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A randomized, double blind trial. Eur J Clin Invest 22:687-691, 1992
14. Sköldstam L, Börjesson O, Kjällman A, et al: Effect of six months of fish oil supplementation in stable rheumatoid arthritis: A double-blind, controlled study. Scand J Rheumatol 21:178-185, 1992
15. Nordström DC, Honkanen VE, Nasu Y, et al: Alpha-linolenic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled and randomized study - Flaxseed vs. safflower seed. Rheumatol Int 14:231-234, 1995
16. Goldberg RJ, Katz J: A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129:210-223, 2007
17. Maroon JC, Bost JW: Omega-3 fatty acids (fish oil) as an anti-inflammatory: An alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol 65:326-331, 2006
18. Kastelein JJ, Maki KC, Susekov A, et al: Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 8:94-106, 2014
19. Ascherio A, Rimm EB, Stampfer MJ, et al: Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 332:977-982, 1995
20. Jula A, Marniemi J, Huupponen R, et al: Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: A randomized controlled trial. JAMA 287:598-605, 2002
21. Wasan KM, Goss PE, Pritchard PH, et al: Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: An NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 136:769-776, 2012
22. Jensen MP, Turner JA, Romano JM, et al: Comparative reliability and validity of chronic pain intensity measures. Pain 83:157-162, 1999
23. Bellamy N, Buchanan WW, Goldsmith CH, et al: Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840, 1988
24. Sautner J, Andel I, Rintelen B, et al: Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology (Oxford) 43:1409-1413, 2004
25. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997
26. Kamper SJ, Maher CG, Mackay G: Global rating of change scales: A review of strengths and weaknesses and considerations for design. J Man Manip Ther 17:163-170, 2009
27. Crew KD, Capodice J, Greenlee H, et al: Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early stage breast cancer. J Clin Oncol 28:1154-1160, 2010
28. Engan T, Krane J, Johannessen DC, et al: Plasma changes in breast cancer patients during endocrine therapy: Lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36:287-297, 1995
29. Friedrichs K, Jänicke F: Aromatase inhibitors: New possibilities in treatment of breast carcinoma [in German]. Praxis (Bern 1994) 87:584-588, 1998
30. Elisaf MS, Bairaktari ET, Nicolaides C, et al: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37:1510-1513, 2001
31. Wampold BE, Minami T, Tierney SC, et al: The placebo is powerful: Estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol 61:835-854, 2005
32. Hróbjartsson A, Gøtzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594-1602, 2001
33. Lethaby A, Marjoribanks J, Kronenberg F, et al: Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 12:CD001395, 2013
34. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
35. Henry NL, Banerjee M, Wicha M, et al: Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117:5469-5475, 2011
36. Nabholtz JM, Gligorov J: Cardiovascular safety profiles of aromatase inhibitors: A comparative review. Drug Saf 29:785-801, 2006
37. Lewis S: Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 153:182-188, 2007
38. Kubo M, Onishi H, Kuroki S, et al: Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32:2331-2336, 2012
39. Monnier A: Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther 6:1653-1662, 2006
40. Dizdar O, Ozçakar L, Malas FU, et al: Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27:4955-4960, 2009
41. Hozumi Y, Hakamata Y, Sasanuma H, et al: Effects of anastrozole on lipid metabolism compared with tamoxifen in rats. Breast Cancer Res Treat 76:131-136, 2002
42. Sestak I, Sapunar F, Cuzick J: Aromatase inhibitor-induced carpal tunnel syndrome: Results from the ATAC trial. J Clin Oncol 27:4961-4965, 2009
43. Laroche M, Borg S, Lassoued S, et al: Joint pain with aromatase inhibitors: Abnormal frequency of Sjogren's syndrome. J Rheumatol 34:2259-2263, 2007
44. US Food and Drug Administration: Safety: Drug safety labeling changes. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm125179.htm